CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.Certain • February 25th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
RE: Collaboration and License Agreement by and among Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. effective October 16, 2017, as amended by letter agreement dated November 13, 2018, Amendment No. 1 to the Collaboration and License Agreement effective December 17, 2019, Amendment No. 2 to the Collaboration and License Agreement effective March 3, 2020 (“Amendment No. 2”) and Amendment No. 3 to the Collaboration and License Agreement effective April 1, 2020 (“Amendment No. 3”) (the “Collaboration Agreement”).
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 25th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment 2”), entered into as of September 28th, 2020 (the “Amendment Date”), and effective as of the Effective Date, is made and entered into by and between The Rockefeller University, a New York not-for-profit education corporation, with a principal place of business at 1230 York Avenue, New York, NY 10065 (“Rockefeller”, also referred to herein as “Licensor”) and Vir Biotechnology, Inc. a Delaware corporation, with a principal place of business at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (referred to herein as “Licensee”).
Amendment Number One to License AgreementLicense Agreement • February 25th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment Number One (“Amendment No. 1”) to the License Agreement dated September 7, 2018 (the “Agreement”), is entered into as of September 1, 2020 (“Amendment No. 1 Effective Date”) by and between MedImmune, LLC, having a principal place of business at One MedImmune Way, Gaithersburg, MD 20878 (“MedImmune”) and Vir Biotechnology, Inc., having a principal place of business at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (“Licensee”). MedImmune and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT INFORMATIONVir Biotechnology, Inc. • February 25th, 2021 • Biological products, (no disgnostic substances)
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.
SUBLEASE BETWEEN DROPBOX, INC. AND VIR BIOTECHNOLOGY, INC.Work Agreement • February 25th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • California
of First Refusal Space upon terms which are, in the aggregate, materially more favorable to a prospective tenant than those in Third Party Proposal (the “Second Chance Economic Terms”), then Sublandlord shall first deliver written notice to Subtenant (“Second Chance Notice”) providing Subtenant with the opportunity to lease the Right of First Refusal on such more favorable terms. For purposes hereof, Second Chance Economic Terms shall be materially more favorable to a third party if such Second Chance Economic Terms reflect a net effective rental rate (including any rent abatement and Tenant Improvement costs/allowance and any other economic concessions) that is less than ninety-five percent (95%) of the net effective rental rate for such space specified in the Third Party Proposal. Subtenant’s failure to elect to lease the Right of First Refusal Space upon such more favorable Second Chance Economic Terms by written notice to Sublandlord within five (5) business days after Subtenant’s
AMENDMENT INFORMATION Agreement to be Amended: Grant agreement between the Bill & Melinda Gates Foundation and Vir Biotechnology Inc, effective January 26, 2018, as amended, and bearing Investment ID INV-010344 (OPP1187970) Amendment Purpose: Change...Vir Biotechnology, Inc. • February 25th, 2021 • Biological products, (no disgnostic substances)
THIS AMENDMENT amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.
